Adicet Bio Engages with Investors at Upcoming Conferences
Adicet Bio, Inc. (NASDAQ: ACET), a pioneering clinical stage biotechnology firm, is making strides in the realm of allogeneic gamma delta T cell therapies aimed at targeting autoimmune disorders and cancer. Recently, the company announced that management will be participating in three prestigious investor conferences slated for the month of November.
Details of the Upcoming Conferences
The company's commitment to engaging with investors is evident through their participation in several influential events. Below are the details of these conferences:
Truist Securities BioPharma Symposium
This event will take place on November 7, where members of Adicet's management will be available for one-on-one meetings with investors, offering an exclusive opportunity to discuss the company's vision and pipeline.
Guggenheim Securities Healthcare Innovation Conference
From November 11 to 13, Adicet Bio will feature prominently at this conference, with Chen Schor, the President and CEO, scheduled to partake in a fireside chat on November 12 at 3:00 p.m. ET. This session promises to provide insights into the company’s progression and future plans.
Jefferies London Healthcare Conference
The European landscape is not being overlooked, as Adicet Bio will also be present at the Jefferies London Healthcare Conference, held from November 19 to 21. During this conference, Chen Schor will again be participating in a fireside chat on November 19 at 12:30 p.m. BST, guiding discussions on innovative approaches in biotechnology.
Accessing the Conference Content
For those interested in following the discussions, live audio webcasts of the fireside chats will be accessible via the Investors section of Adicet Bio's official website. Furthermore, an archived version will be made available for 30 days following the presentations.
About Adicet Bio, Inc.
Founded with the aim of transforming healthcare, Adicet Bio, Inc. is at the forefront of research and development, concentrating on allogeneic gamma delta T cell therapies. With their pipeline of 'off-the-shelf' gamma delta T cells, which are engineered with chimeric antigen receptors (CARs), Adicet is poised to offer actionable treatments for various conditions.
As the company progresses, its innovative strategies and scientific endeavors are set to reshape the landscape of therapies for autoimmune diseases and cancer, providing hope for many patients.
Frequently Asked Questions
What is Adicet Bio's core business focus?
Adicet Bio is primarily focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Which event will the CEO of Adicet Bio participate in?
Chen Schor, the CEO, will participate in fireside chats at both the Guggenheim Securities Healthcare Innovation Conference and the Jefferies London Healthcare Conference.
What is the significance of the Truist Securities BioPharma Symposium for Adicet Bio?
This symposium provides a platform for Adicet's management to engage directly with investors through one-on-one meetings, discussing their innovative therapies and company strategies.
How can investors access the conference webcasts?
Investors can access the live audio webcasts of the fireside chats through the Investors section of Adicet Bio’s official website.
What are 'off-the-shelf' gamma delta T cells?
'Off-the-shelf' gamma delta T cells refer to therapies that can be readily available for patients, engineered to enhance therapeutic effectiveness against targeted diseases.